AI Terminal
Ananda Pharma Plc
Report Publication Announcement • Aug 19, 2025
10286_rns_2025-08-19_472241bc-0138-47a7-8a76-a0cf7be61016.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7689V
Ananda Pharma PLC
19 August 2025
19 August 202 5
ANANDA PHARMA PLC
("Ananda" or the "Company")
Webinar Presentation Release
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate update presentation delivered on 12 August 2025 has been posted to the Company's website and is available to read here: https://investors.anandapharma.co.uk/webinars/WPGNwr-post-annual-report-corporate-update-and-q-a .
At this link, it will be possible to watch a recording of the presentation and ask a question which will be responded to, on the Company's Investor Hub, by management.
The Company's CEO and the presenter, Melissa Sturgess, said: 'It's a decent feeling to signpost our achievements over the past 12 months and highlight our objectives for the next 6 months.
Our achievements include:
- raising £2.38m from new and existing shareholders
- being confirmed as the supplier of our MRX2 CBD & MRX2T CBD/THC formulations to two Phase 3a placebo controlled clinical trials into epilepsy
- the appointment as Advisors of 2 ex senior GW Pharmaceuticals executives
- Ethics Approval granted for our Phase 1 pharmacokinetic study in Australia
- delivery of MRX1 CBD to the trial site in Australia
- commencement of dosing in the Phase 1 study in Australia
All this is in the quest to get our MRX1 CBD through clinical trials and FDA regulatory approvals.
It's a reasonably short 20min update and 10 min of Q&A. We hope you find it useful.'
About Ananda Pharma
Ananda Pharma (AQSE: ANA, OCT: ANANF) is a UK-based biopharmaceutical company developing regulatory approved , cannabidiol medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.
For more information, please visit our website :
To stay up to date with Ananda's news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn : https://www.linkedin.com/company/anandapharma
· X : https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
| ANANDA PHARMA PLC | +44 (0)7463 686 497 |
| [email protected] | |
| Chief Executive Officer | |
| Melissa Sturgess | |
| Finance Director | |
| Jeremy Sturgess-Smith | |
| SP ANGEL CORPORATE FINANCE LLP | |
| Corporate Finance | +44 (0)20 3470 0470 |
| Richard Morrison | |
| Josh Ray | |
| Corporate Broking | +44 (0)20 3470 0534 |
| Vadim Alexandre | |
| Abigail Wayne | |
| Rob Rees | |
| VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper |
+1 (646) 330-0704 [email protected] |
| YELLOW JERSEY PR Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 [email protected] |
https://investors.anandapharma.co.uk/link/P76mKr
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAXVLFFEVLLBBV